Effectiveness and safety of transcutaneous auricular vagus nerve stimulation for depression in patients with epilepsy
Epilepsy & Behavior · 2025
DOI: 10.1016/j.yebeh.2024.110226 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Epilepsy & Behavior, 2025. Verfasst von Zheng Yan Ran Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Epilepsy Center, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Depression, Epilepsy, Transcutaneous Electric Nerve Stimulation, Vagus Nerve Stimulation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Zhejiang Province, Science and Technology Program of Zhejiang Province.
Themen: Depression
Abstract (Originalsprache)
OBJECTIVE: Our study aimed to evaluate the effectiveness and safety of transcutaneous auricular vagus nerve stimulation (taVNS) for treating mild to moderate depression in patients with epilepsy (PWE). METHODS: A single-arm, prospective, multi-center, pre-post controlled study was conducted in Eastern China. After a four-week baseline period, PWE with mild to moderate depression began treatment with taVNS, administered for 30 min, three times daily, over a 12-week period. The primary outcome measure was the change in 24-item Hamilton Depression Rating Scale (HAMD) scores from baseline to week 12. Secondary outcomes included the response and remission rates for depression at week 12, as well as changes in the 14-item Hamilton Anxiety Rating Scale (HAMA), the Pittsburgh Sleep Quality Index (PSQI), and the Quality of Life in Epilepsy Inventory-31 (QOLIE-31) scores, and seizure frequency at weeks 4 and 12 compared to baseline. Adverse events (AEs) were recorded to assess the safety of taVNS. Both modified Intention-To-Treat (mITT) and Per-Protocol (PP) analyses were employed. RESULTS: Sixty-nine participants were enrolled in this study. Of these, 61 (88.4 %) completed the 4-week treatment phase, and 50 (72.5 %) finished the 12-week treatment phase. In the mITT analysis, HAMD scores significantly decreased by 4.54 ± 7.44 (p < 0.001) from baseline to week 12, with clinical response in 16 (26.2 %) and remission in 15 (24.6 %) patients. HAMA scores also decreased significantly by week 4 (3.23 ± 5.18, p < 0.001) and week 12 (4.95 ± 6.78, p < 0.001). PSQI scores and seizure frequency showed non-significant changes at week 4, but seizure frequency decreased significantly by week 12 (0.03 ± 10.47, p = 0.038). In the PP analysis, similar improvements were observed. After 12 weeks of taVNS compared to baseline, HAMD scores decreased significantly by 5.32 ± 8.98 (p < 0.001), with 32 % of patients achieving a clinical response and 24 % achieving clinical remission. And HAMA scores also decreased by 5.66 ± 7.54 (p < 0.001), seizure frequency by 0.14 ± 11.03 (p = 0.018), and PSQI scores by 1.06 ± 4.14 (p = 0.076).There was a significant increase in QOLIE-31 scores by 5.17 ± 14.71 (p = 0.020). Ten (14.5 %) patients experienced non-serious adverse events, the most common of which was ear pain (n = 4); one patient withdrew due to tinnitus enhancement; all resolved after reducing the stimulation intensity or stopping the treatment. CONCLUSION: Our study suggests that taVNS may effectively improve depressive symptoms in PWE. This may be an efficacious and safe treatment for mild to moderate depression in PWE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Epilepsy Center, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- Department of Neurology, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, China.
- Department of Neurology, Li Huili Hospital, Ningbo Medical Center, Ningbo, China.
- Department of Neurology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Department of Neurology, Dongyang People's Hospital, Jinhua, China.
- Department of Neurology, Jinhua Second People's Hospital, Jinhua, China.
Förderung
- National Natural Science Foundation of China
- Science and Technology Department of Zhejiang Province
- Science and Technology Program of Zhejiang Province
Zitieren
APA
Xu, Z. Y. R., Fang, J. J., Fan, X. Q., Xu, L. L., Jin, G. F., Lei, M. H., Wang, Y. F., Liu, J. B., Dong, F., Jiang, L. R., & Guo, Y. (2025). Effectiveness and safety of transcutaneous auricular vagus nerve stimulation for depression in patients with epilepsy. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2024.110226
Vancouver
Xu ZYR, Fang JJ, Fan XQ, Xu LL, Jin GF, Lei MH, et al. Effectiveness and safety of transcutaneous auricular vagus nerve stimulation for depression in patients with epilepsy. Epilepsy & Behavior. 2025. doi:10.1016/j.yebeh.2024.110226
BibTeX
@article{Xu2025,
author = {Xu, Zheng Yan Ran and Fang, Jia Jia and Fan, Xiao Qin and Xu, Long Long and Jin, Gui Fang and Lei, Mei Hua and Wang, Yu Fei and Liu, Jun Biao and Dong, Fang and Jiang, Lu Rong and Guo, Yi},
title = {Effectiveness and safety of transcutaneous auricular vagus nerve stimulation for depression in patients with epilepsy},
journal = {Epilepsy & Behavior},
year = {2025},
doi = {10.1016/j.yebeh.2024.110226}
}
EUVIMED